In this study, we review the current knowledge and recent insights on the role of epigenetic factors in the development of human insulin resistance (IR)-and metabolic syndrome (MS)-related phenotypes, and attempt to lay a framework to consider IR as a potentially reversible incapacity to control metabolic homeostasis that is strongly infl uenced by the interplay between external and internal cues. We summarize the evidence on how tissue-specifi c epigenetic markers participate either by activating or repressing the gene expression programs to modulate IR-and MS-associated traits. Some additional data are provided about how the exploration of DNA methylation markers in peripheral blood mononuclear cells potentially offers appealing information about the impact of epigenetics in the pathogenesis of IR. Clues about the relation between IR and impaired intrauterine growth explained by fetal metabolic programming and epigenetic modifi cations are shown, including novel fi ndings about the impact of histone modifi cations. For instance, we observed that specifi c epigenetic factors in genes associated with mitochondrial biogenesis may be associated with birth weight. Furthermore, some prospective ideas about the functional consequences of genetic variation modulated by allele-specifi c epigenetic markers and its impact on MS susceptibility are also illustrated. Finally, we summarize the current knowledge of epigenetics as the biological rationale for potential therapeutic intervention in IR and MS.
Introduction
Metabolic syndrome (MS) is associated with several metabolic disturbances, including insulin resistance (IR) in several tissues. Indeed, IR is considered as the main link among all the clinical disorders clustered in MS, namely type 2 diabetes (T2D), dyslipidemias, central obesity, arterial hypertension, prothrombotic and proinfl ammatory states, ovarian polycystosis, and non-alcoholic fatty liver disease (NAFLD). From the perspective of clinical importance, MS has two prominent features: its worldwide prevalence that is dramatically increasing and its strong association with cardiovascular disease, as initially described by Reaven (1) .
It is broadly accepted that IR results from a complex interplay between genes and environment; however, despite signifi cant efforts, the understanding of its pathogenesis remains a major challenge. In fact, while both genome-wide and candidate gene association studies have identifi ed several loci that infl uence the susceptibility of all the clustering traits of MS, they have also demonstrated that the identifi ed loci only explain < 10 % of the population variance (2, 3) , owing to the fact that the reported effect size of the gene variants is modest, as shown, for example, for T2D and other components of MS (2, 4) .
Likewise, environmental factors, such as decreased physical activity, increased nutrient availability and overnutrition, play an important role in the development of metabolic disturbances associated with IR and are also largely recognized as being responsible for the modern epidemic of MS-related phenotypes. Nevertheless, they do not explain the pathophysiology of IR and MS. This is, in part, because of the fact that the environmental factors operate at different levels, and its infl uence is even more signifi cant in a genetically predisposed background because of an important individual susceptibility as observed from twins studies, although this concept has been recently challenged (5, 6) . Hence, it is reasonable to speculate that the gene-environment interaction is a strong modifi er of the IR state, and this interaction is modulated by epigenetic mechanisms.
Why is epigenetics important to understand the pathophysiology of IR ? Not only because of the biological plausibility but also because epigenetic modifi cations regulate gene transcription, regulate chromosome organization, are highly regulated by environmental stimuli, including nutritional status, are highly dynamic, may operate in a tissue-specifi c manner, and while epigenetic changes are heritable across cell division, they can also occur de novo .
Cytosine (C) methylation (5-methylcytosine) is a common epigenetic modifi cation, where a C is adjacent to a guanine (G) nucleotide (CpG). Around 5 % of cytosines are methylated, and nearly 50 % -60 % of genes have CpG-rich islands (regions of typically 300 -3000 bp in length with a high content of CpG and C/G % in their fi ve untranslated regions). During fetal development as well as in adult life, normal somatic cells (and also cancer cells) exhibit alterations in DNA methylation induced by environmental stimuli. As CpGs are paired by GC in the opposite strand, methylation in one strand is mirrored by methylation in the other. During replication, methylation in the parent strands directs methylation in the newly replicated DNA by recruiting DNA methyltransferases (DNMTs). Subsequently, stable transfer of gene methylation patterns to progeny lines is accomplished. CpG methylation is thought to constrain expansive regions of the genome by silencing repetitive sequences or repressing promoters by recruiting methyl-CpG binding proteins (MBD protein family). Although methylation is associated with repressed promoters, transcriptional repression via histone methylation and acetylation precedes DNA methylation. Interested readers can fi nd several excellent reviews on this issue in the literature; owing to space constraints, we have just mentioned two in this study (7, 8) . A short overview on the main features of epigenetic modifi cations is shown in Table 1 . • HATs can be divided into several families, including the PCAF/ Gcn5, p300/CBP, MYST, SRC, TAFII250, HAT1, and ATF-2 families • HDACs are classifi ed into four groups (I -IV)
In this study, we review the current knowledge and recent insights on the role of epigenetic factors in the development of human IR-and MS-related phenotypes, and attempt to lay a framework to consider that IR is a potentially reversible incapacity to control the metabolic homeostasis that is strongly infl uenced by the interplay between external and internal cues.
Peroxisome proliferator-activated receptor γ coactivator 1 α ( PPARGC1A ) is a target gene of epigenetic modifi cations in MS-related phenotypes
The transcriptional coactivator, peroxisome proliferatoractivated receptor γ coactivator 1 α ( PPARGC1A ) coordinates the regulation of genes involved in energy metabolism by controlling transcriptional programs of mitochondrial biogenesis, adaptive thermogenesis and fatty acid β oxidation. In fact, its tissue specifi city pattern of expression is mainly located in the heart, skeletal muscle, liver and kidney (9) . Interestingly, the protein encoded by this gene is involved in controlling blood pressure, regulating cellular cholesterol homoeostasis and development of obesity, and altered signaling of PPARGC1A contributes to glucose intolerance, IR and T2D (10) . Not surprisingly, this gene has been the most chosen candidate gene for the evaluation of epigenetic modifi cations in human phenotypes associated with IR and MS (Figure 1 ). For instance, we had demonstrated for the fi rst time that in the liver of patients with NAFLD, the methylation status of the PPARGC1A promoter is signifi cantly associated with plasma fasting insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR) (11 Figure 1 Role of DNA methylation status of target genes in the development of human IR-and MS-related phenotypes: summary of current knowledge. Several tissues are shown, such as liver (1) , skeletal muscle (2) , pancreatic islets (3) , adipose tissue (4), white cells of the blood (5), umbilical cord (6) and placenta (7) where the status of promoter DNA methylation of some candidate genes was explored in humans. The effect of DNA methylation in some tissues signifi cantly impacts on modulation of gene transcription, for example, liver, skeletal muscle, pancreatic islets and adipose tissue. In some other tissues or cells, the consequences of DNA methylation of candidate genes remain unexplored, for example, white cells of the blood, umbilical cord and placenta. The resulting phenotypes substantially vary according to the target tissue and the target gene, for instance, DNA methylation of the PPARGC1A promoter in the liver, skeletal muscle and pancreas directly impacts on modulation of the status of insulin resistance (solid arrows) or indirectly by modulation of mitochondrial biogenesis (dashed arrows) or obesity. Some evidence on modulation of the promoter activity of PPARGC1A in skeletal muscle by lifestyle modifi cations, such as physical activity or weight reduction programs, is also shown. Finally, evidence on allele-specifi c DNA methylation of selected genes, such as FTO and MCHR1, and the role of DNA methylation of candidate genes in metabolic programming is also provided. Citations of each tissue or cell are shown as follows: fatty liver (11) , skeletal muscle (13, 15, 72, 73) , pancreatic islets (12, 18) , adipose tissue (16) , peripheral white blood cells (22, 23, 25, 26, 33, 74) , blood umbilical cord and placenta (34, 39) .
islets of patients with T2D, Ling et al. observed high levels of DNA methylation of the PPARGC1A promoter (12) (Figure 1 ). Interestingly, Barres et al. observed that in vastus lateralis muscle biopsies of patients with T2D, the promoter of PPARGC1A was hypermethylated, but surprisingly, most of the methylated cytosines were found within the non-CpG dinucleotides (13) . In fact, by whole-genome methylation using luminometric methylation assays, the authors found that global CpA and CpT methylation was increased, although CpG methylation was unaltered (13) . If replicated in other tissues, this fi nding might have important biological implications because cytosine-5 methylation at CpA and, to a lesser extent, at CpT, is almost confi ned to embryonic stem cells, but not somatic tissues (14) .
An important fi nding to highlight is that in addition to an impact on the phenotype, the methylation status of the PPARGC1A promoter was observed to be inversely correlated with the expression of the mRNA in all the above-mentioned tissues (11 -13) . Perhaps, the most remarkable observation is that in the liver of NALFD patients and in the muscle of T2D patients, a tight interaction between the transcriptional activity of PPARGC1A and the mitochondrial DNA copy number was noted, which had a direct impact on the status of IR (11, 13) (Figure 1 ).
Finally, a remarkable fi nding about the potential modulation of the PPARGC1A gene by external cues was reported by Alibegovic et al., who showed that IR induced by physical inactivity is associated with multiple transcriptional changes in the skeletal muscle in young men, which had a direct impact on mitochondrial function (15) . The authors also showed a trend towards increased PPARGC1A DNA methylation after bed rest (15) (Figure 1 ).
Epigenetic markers encompass tissue-specifi c effects that independently modulate the status of insulin resistance
The metabolic state known as IR is actually a systemic failure to respond to physiological levels of insulin, leading to a global dysregulation in the ability of the target tissues to maintain the equilibrium among storage, mobilization and utilization of energy fuels, such as glucose and free fatty acids. Thus, at least three tissues are involved, namely, muscle, liver and adipose tissue. Nevertheless, although the ultimate consequence is the loss of insulin capability to maintain normal glucose metabolism, each tissue has its own profi le of activated or repressed genes, because each tissue needs to adapt to its physiological functions. Hence, epigenetic markers are either cell-or tissue-specifi c to activate or repress their own gene expression programs.
A clear example of this observation is the report by Fujiki et al., who demonstrated that in 3T3-L1 preadipocytes, the promoter of the proliferator-activated receptor γ 2 ( PPARG2 ) is hypermethylated, but this state changes progressively and becomes demethylated upon induction of differentiation, which is accompanied by an increase in PPARG2 mRNA expression (16) . Interestingly, the expression of the PPARG2 isoform in the adipose tissue was found to be regulated at the transcriptional level by nutrition (17) . Kuroda Maternal IR is an important player in the development of gestational diabetes, and most of the cellular mediators of IR in this condition are placental-derived hormones. Bouchard et al. recently reported an interesting association between leptin gene DNA methylation in placenta and gestational impaired glucose tolerance (19) . Despite this signifi cant association between placental DNA methylation and the mother ' s glycemia during pregnancy, it requires further investigation; the fi nding opens an interesting question on the role of epigenetic modulation of leptin levels during pregnancy by a tissue that normally produces high levels of leptin, which is also highly associated with newborn birth weight, and is involved in human perinatal morbidity and mortality.
Another interesting topic for discussion is the fact that patterns of DNA methylation are variable between individuals and ' epigenotypes ' may contribute to the susceptibility of complex diseases (20) . A recent report on whole-genome DNA methylation analysis (methylome) in human peripheral blood mononuclear cells (PBMCs) demonstrated that this methylome is rich in biological information (21) . Li et al. also observed that 68.4 % of CpG sites and 0.2 % of non-CpG sites were methylated, demonstrating that non-CpG cytosine methylation is minor in human PBMCs (21) . Based on these fi ndings, the analysis of the methylation pattern in PBMCs of candidate genes could be very informative. Moreover, PBMCs are readily accessible and most of the Biobanks around the world might have access to them. A clear example of the potentially appealing information on DNA methylation markers in PBMCs and MS-related phenotypes is given in the following paragraph.
We evaluated the DNA methylation status of the transcription factor A mitochondrial ( TFAM) promoter in PBMCs of adolescents with features of MS, and observed an inverse correlation with IR, considering either metabolic quantitative traits (fasting insulin and glucose levels and HOMA index) or IR as a dichotomous condition (22) . In fact, the ratio of the promoter methylated DNA / unmethylated DNA was 0.012 ± 0.0009 (1.2 % of alleles) and inversely correlated with the biochemical features of IR (plasma fasting insulin: R = -0.26, p < 0.004; HOMA index: R = -0.27, p < 0.002) and obesity (R = -0.27, p < 0.002) (22) .
Another study provided evidence that obesity is associated with methylation changes in two immune-related genes, UBASH3A and TRIM3 , in blood leukocyte DNA and suggested an interesting role of obesity-induced immune dysfunction (23) .
Epigenetics and genetic variation: how are epigenomics and genomics integrated to understand the susceptibility to MS-related phenotypes ?
Epigenetic markers can also give us a mechanistic explanation about how single nucleotide polymorphisms (SNPs) may infl uence the genetic susceptibility of common diseases, because it was shown that differential DNA methylation between alleles is not restricted to imprinted genes or the female X chromosome (24) . In fact, recent evidence showed that approximately 10 % of autosome human genes may be affected by allele-specifi c methylation (24) . This fi nding is also relevant because allele-specifi c gene expression contributes not only to common diseases but also to inter-individual differences in disease susceptibility.
Robust examples of two candidate loci involved in MS-related diseases, such as fat mass and obesity associated ( FTO ) and melanin-concentrating hormone receptor 1 ( MCHR1 ), which show allele-specifi c DNA methylation, are given in the following paragraphs.
For instance, by evaluating the density of methylated CpGs in the whole blood genomic DNA from Caucasian individuals, Bell et al. recently reported an increased DNA methylation on the obesity susceptibility FTO haplotype, tagged by the rs8050136 risk allele A (25) .
Stepanow et al. performed methylation analysis of a CpG island in the fi rst exon of the MCHR1 encompassing the rs133072 and rs133073, a gene involved in the control of energy metabolism and linked to obesity, and found that MCHR1 methylation is allele-specifi c, age-dependent, BMIassociated and affects gene expression (26) .
IR and impaired intrauterine growth: fetal metabolic programming and epigenetic modifi cations
A growing body of evidence supports the notion that epigenetic alterations, such as DNA methylation and histone modifi cations, which mediate phenomena, such as genomic imprinting, may also contribute to metabolic programming (27) . Perhaps, the most important consequence of metabolic programming is the transmission of the phenotype from mother to the progeny and even through generations (27) . This observation has a direct impact on public health as epidemiological data show that impaired intrauterine growth and adult metabolic and cardiovascular disorders, including T2D and IR, are strongly associated (28 -30) .
The concept of metabolic programming presumes a permanent change of the metabolism of the newborns exposed to an adverse intrauterine environment that continues to be expressed even without the original stimulus. Although this premise has been well documented in rodents (27, 31) , few human studies have examined the interplay between an adverse in utero environment and epigenetic modifi cations as a potential mechanism to explain the later development of MS-related phenotypes.
The most robust observation about the infl uence of the prenatal environment on DNA methylation came from epigenetic studies that examined individuals who were exposed to famine during gestation, such as the Dutch famine at the end of World War II, which affected the western part of The Netherlands from 1944 to 1945 (32) (Figure 1 ). IGF2 encodes a member of the insulin family of polypeptide growth factors that are involved in development and growth; it is an imprinted gene, expressed only from the paternal allele. To further explore the associations between prenatal famine (as low as 500 kcal/day) and DNA methylation of non-essential imprinted genes, in the Hunger Winter Families Study, Tobi et al. assessed the methylation state in the regions of 15 candidate genes involved in metabolic and cardiovascular disease, and observed that six loci showed signifi cant differences in DNA methylation after famine exposure during periconception ( INSIGF , GNASAS , MEG3 , IL10 , LEP and ABCA1 ); interestingly, three of the loci ( INSIGF , GNASAS and LEP ) differed by sex (34) (Figure 1 ) . The methylation status of just one locus, GNASAS , was associated with exposure to famine late in gestation (34) ; this gene produces a paternally imprinted antisense RNA transcript that helps to regulate the GNAS complex locus that encodes the α subunit of the stimulatory G protein.
Likewise, infants who are born either with low birth weight (29) (small for gestational age, SGA) or are large for gestational age (LGA) (35) are at an increased risk of developing MS and its complications (36) .
This association between birth weight and adult chronic diseases also demonstrates the concept of metabolic programming. In fact, the epidemiological evidence on the relationship between abnormal fetal growth and adult disease replicated all around the world (37, 38) illustrates the importance of the in utero nutritional environment in the modulation of the adult phenotype, and suggests the induction of epigenetic markers that reprogram the metabolic machinery of the offspring.
An interesting premise to follow-up is how and why both extremes of fetal growth are connected by a common outcome. In this context, a reasonable question arises.
Does DNA methylation connect both extremes of abnormal fetal growth with metabolic programming ?
To answer this question, we recently examined the status of differential DNA methylation in master genes that control either mitochondrial number -such as TFAM -or mitochondrial function, adaptive thermogenesis, glucose and fat oxidation in muscle and fat tissue, and gluconeogenesis in liver -such as PPARGC1A -or adipogenesis and insulin signaling, such as PPARG in umbilical cord of newborns between the extremes of abnormal fetal growth, namely SGA and LGA (39) . We also evaluated the relationship between the methylation status of the promoter of these genes and the mother ' s pre-pregnant characteristics (39) . Interestingly, we observed a positive correlation between maternal body mass index (BMI), which suggests a potential role of PPARGC1A methylation in the metabolic programming of the fetus (39) . In addition, a novel aspect of our fi ndings is the evaluation of epigenetic markers in the DNA of the umbilical cord, which is a crucial link between the mother and the fetus during pregnancy. An interesting aspect worth mentioning is that the PPARGC1A promoter methylation in the umbilical cord is modifi ed by the presence of homozygosity to the rs8050136 risk allele A of the FTO , in particular, in the LGA offspring, which indicates that FTO may act by altering DNA methylation of metabolic relevant genes. FTO is a nuclear protein of the AlkB-related non-heme iron and 2-oxoglutarate-dependent oxygenase superfamily, but the exact physiological function of this gene is unknown. As other non-heme iron enzymes function to reverse alkylated DNA and RNA damage by oxidative demethylation, it is rational to hypothesize that FTO, with other proteins of the TET (ten-eleven-translocation) oncogene family and Jumonji C domain-containing proteins, may participate in the metabolism of another recently described epigenetic marker, 5-hydroxymethyl-cytosine, which may be an intermediate in the demethylation process and may be altered in malignancies (40, 41) .
Under the same hypothesis that individuals born with low birth weight (LBW) are at increased risk of developing IR, T2D and MS later in life, Brons et al. hypothesized that young and healthy LBW subjects show altered DNA methylation in the promoter region of PPARGC1A (42) (Figure 1 ) . Thus, the authors performed an evaluation of the status of PPARGC1A methylation in the skeletal muscle in subjects during a control diet as well as after the exposure to a diet high in fat and calories for a 5-day period (42) . The results of this study showed that LBW subjects had elevated DNA methylation of the PPARGC1A promoter at baseline, and this status modulated PPARGC1A mRNA expression when challenged by a high-fat overfeeding diet (42) .
The evidence showing that the maternal environment alters the fetus growth also suggests the concept of ' parental effect ' that is defi ned as the effect on the phenotype of the offspring, which is determined by the genotype or environment experience of the parents (43) . The most clear example of this concept is the infl uence of maternal environment on the development of fetus adiposity, which shows that underweight mothers are more likely to give birth to lower weight infants and overweight women are more likely to give birth to larger infants (44) . We also observed that maternal pre-gestational BMI is associated with the weight of their offspring, and SGA babies had lean mothers (BMI = 21.4 ± 0.7) and LGA babies had overweight mothers (BMI = 26.7 ± 1.4), when compared with babies with appropriate weight for gestational age (BMI = 23.0 ± 0.7; p < 0.003) (45) . Furthermore, weight of newborns may be predicted from the weight of previous offspring.
After reviewing the current data about the association between fetal programming, adult disease, and changes in the status of DNA methylation in candidate genes, another interesting question arises.
Do post-transcriptional histone modifi cations play a role in human fetal programming ?
Around 10 years ago, Jenuwein and Allis postulated the ' histone code ' hypothesis (46) . According to the hypothesis, chromatin structure is regulated by a specifi c combination of histone modifi cations. Currently, histone modifi cations are considered to be central epigenetic markers. In fact, several dynamic post-translational covalent reactions (acetylation, methylation, phosphorylation, ubiquitylation, SUMOylation, ADP ribosylation, deamination and proline isomerization) have been reported in the histone tails, the histone N-terminals that protrude from the nucleosome, a portion of 166 bp DNA wrapping of histone octamers (two molecules of histones 2a, 2b, 3 and 4). The acetylation of histone Lys (K) is associated with activation of adjacent chromatin regions, whereas the opposite is closely related to inactivated chromatin states.
Previously, histone acetylation was considered to be a hallmark of transcriptional activation. However, detailed investigation has revealed that histone methylation at specifi c amino acid residues, mainly K, in histone N-terminal tails is an important modifi cation defi ning chromatin state (47) . Methylations at H3 lysine 4 (H3K4) and lysine 36 (H3K36) appear to be signals of chromatin activation, whereas methylation of H3K9 and H3K27 seems to be related to chromatin condensation. A further complexity is added by the fact that one to three methyl radicals could be added (Me1, Me2 or Me3).
Unfortunately, how histone modifi cations impact the human fetal programming remains poorly understood and, to the best of our knowledge, the only evidence about a possible association comes from animal studies (48) .
Therefore, to investigate the patterns of histone methylations across the promoter of PPARGC1A (from -320 to -700 bp from the transcription start site) and TFAM (from -512 to -930 bp from the transcription start site) genes in newborns exposed to different prenatal environments, we extracted DNA with or without chromatin enrichment in specifi c histone modifi cations by chromatin immunoprecipitation (CHIP) from the cell nuclei of the umbilical cord. In this analysis, we evaluated 50 newborns, including 16 with appropriate weight for gestational age and 34 representing both the extremes of abnormal fetal growth: SGA ( n = 17) and LGA ( n = 17). We used antibodies specifi c for modifi ed H3, such as H3K4Me3 and H3K9Me3 (Active Motif, Carlsbad, CA, USA). Specifi c gene abundance in the immunoprecipitated chromatin against the input, non-enriched chromatin, was evaluated by real-time qPCR. Interestingly, we observed that the H3K4Me3-related TFAM promoter is associated with birth weight (Wilks = 0.60, p < 0.014); two different segments of the promoter were perfectly correlated (Spearman R = 0.89, p < 0.0000001; unpublished data).
Previous evidence from our group (49) and others (50) showed that the missense Gly482 Ser (rs8192678) variant in PPARGC1A is associated with features of MS. These fi ndings prompted us to explore a potential relationship between the status of histone methylation in the PPARGC1A promoter and the Gly482Ser genotypes. Using antibodies specifi c to H3K9 Me3, we observed signifi cant differences between alleles showing that carriers of the 482Ser allele had 50 % (p < 0.02) less H3K9 Me3-associated PPARGC1A promoter regions than the non-carriers. This novel fi nding suggests an interesting interaction between post-transcriptional histone modifi cations and Gly482 Ser polymorphism in PPARGC1A , because H3K9 trimethylation is usually associated with gene repression. Hence, our data might indicate an allele-specifi c chromatin modifi cation. Although these data must be investigated further, they suggest that potential phosphorylation of the PPARGC1A 482Ser (as predicted in silico ) by kinases, such as CKII, may modulate its own expression by inducing chromatin modifi cations. In fact, PPARGC1A is one of the best-characterized nuclear receptor coactivators by docking histone acetylases or other coregulators (51) . Although the majority of these regulatory subunits remain to be characterized, in silico analysis (52) showed that PPARGC1A is a central regulator of chromatin modifi cations, exhibiting important interactions with other nuclear receptors, DNA methylases, histone acetylases and deacetylases (Figure 2 ).
Expert opinion Do tissue specifi c or global deviations from the physiological epigenome explain IR ?
The pathogenesis of peripheral IR is strongly associated with the ability of the liver to suppress endogenous glucose production, suggesting that this organ is a key player in this scenario. Some metabolic disturbances in the hepatic tissue, such as abnormal triglycerides accumulation observed in fatty liver, have been suggested as the trigger events and perhaps the causative factors of IR (53 -55) . In addition, NAFLD represents the hepatic component of the MS, and IR is a hallmark feature in the pathophysiology of NAFLD. Despite all the Figure 2 Network predicted by VisANT web-based software (52) using PPARGC1A and putative histone methylases and demethylases listed in Table 1 of Ref. (51) . Other DNA-binding transcriptional regulatory factors, nuclear receptors, such as androgen receptor (AR), estrogen receptors (ESRs), PPARs, etc., and coregulators, such as PPARGC1A, for ligand-dependent and -independent gene regulation require basic transcription factors and RNA polymerases. In addition, they must interact with histone acetylases, methylases and demethylases to modify chromatin structure to modulate gene transcription. DNA methylation is another epigenetic marker that plays a role in this process through the action of DNA methylases (DNMTs) and demethylases (TET and Jumonji-domain protein families). Most of the names of the nodes have been removed for the sake of simplicity and just to show that in the past two decades, more than 300 nuclear receptors and their coregulators have been described being PPARGC1A, one of the central ones in connecting gene transcription with metabolic status. evidence, how IR and NAFLD are connected remains inconclusive. In this context, we hypothesized that NAFLD and IR are strongly linked by epigenetic modifi cations that act as a potential modifi er of both conditions, and observed that methylation levels of the PPARGC1A promoter in the liver tissue of NAFLD patients are correlated with HOMA-IR and plasma fasting insulin levels (11) . Interestingly, we also observed that liver abundance of PPARGC1A mRNA is inversely correlated with the methylation levels of PPARGC1A promoter CpGs, and also with the status of peripheral IR, suggesting that methylation of, at least, three explored CpG sites in the gene promoter effi ciently repressed its transcriptional activity (11) . Finally, we were able to show that mitochondrial biogenesis is reduced in the liver of NAFLD patients and is associated with peripheral IR and PPARGC1A promoter methylation status.
Do targeting epigenetic modifi cations have any potential as a therapeutic intervention in IR ?
Epigenetics has emerged as an important fi eld in the therapeutic intervention of chronic human diseases because it offers a unique framework of potentially heritable, but reversible mechanisms that modulate cellular transcriptional machinery and then command signatures of tissue gene expression.
There are currently two classes of compounds that interfere with the epigenetic process, DNA methyltransferase (DNMTs) and histone deacetylase (HDAC) inhibitors, but both approaches are currently directed to the treatment of cancer. A major question in this fi eld is whether targeting epigenetics does not compromise, or alter, the transcription program of non-targeted tissues. For example, targeting epigenetic modifi cations using DNMT inhibitors is probably hampered by the potential inherent toxicity of inhibiting global genomic DNA methylation at ' non-affected cells ' . Similar concern is attributed to many HDAC inhibitors as they can disrupt the function of healthy cells.
Nevertheless, targeting epigenetics in the fi eld of metabolic diseases, such as MS-related traits, has tremendous potential. In the previous sections of this review, we provided evidence that epigenetic markers associated with IR are characterized by global changes of a target gene: the transcriptional coactivator PPARGC1A . As shown in Figure 3 , we speculate on the potential of PPARGC1A as the target for epigenetically active drugs by the modulation of the acetylation/deacetylation switch mediated by Class III HDACs of the NAD + -dependent SIR family.
Post-translational modifi cations of PPARGC1A play a key role in the induction of the PPARGC1A promoter, either by direct phosphorylation mediated by AMPK or by deacetylation mediated by NAD-dependent deacetylase SIRT1 (56, 57) ; these events directly ameliorat IR, enhancing mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) capacity, and modulating fatty acid oxidation. The group of Class III HDACs is composed of seven mammalian sirtuins (SIRT1 -7), which are nicotinamide adenine dinucleotide (NAD + )-dependent protein deacetylases; SIRT1 is the enzyme that mediates the (NAD + )-dependent deacetylation of PPARGC1A (58) . PPARGC1A is, in addition, directly acetylated by another acetyltransferase enzyme, such as General Control Nonderepressible 5 (GCN5) (59) , a process that results in a transcriptional repression of the PPARGC1A (Figure 3 ) . Moreover, there is evidence that some protein substrates of HDACs participate in the transcriptional machinery of several genes modulated by PPARGC1A; for example, glucocorticoid receptor (GR) is a substrate of HDAC2 (60) and HDAC8 and SIRT1 interact directly with estrogen-related receptor α (ERR α ) in vivo and deacetylate and increase the DNA-binding affi nity of ERR α in vitro (61) . Hypoxia inducible factor 1 α (HIF1 α ) is also a protein substrate of HDACs (62) , which takes part in a critical process in the mechanism underlying HIF1 α stability; and PPARGC1A also indirectly modulates HIF1 α signaling to adapt mitochondrial demands (63) (Figure 3 ) .
Finally, there are several compounds that regulate the action of HDACs; among them, resveratrol (Figure 3 ) , a natural compound mainly found in the skin of grapes with antioxidant properties, has been found to be associated with a decrease in PPARGC1A acetylation and an increase in PPARGC1A activity (64) .
Outlook Challenge for the future: modulation of IR in the central nervous system by epigenetic modifi cations
Examining epigenetic markers not only in the periphery but also in the central nervous system might draw the epidemiological link between fetal programming and MS in adulthood. We suggest that a putative mechanism through which fetal programming can contribute to the development of obesity and IR in adult life may stem from epigenetic modifi cations in tissues, which orchestrate the endocrine system, modify the energy balance and have a direct connection with the visceral organs. This concept places the hypothalamus and the diencephalon in a central position, as they are potentially able to sense nutrient status. Under this premise, in a rat model, we investigated the impact of developmental and long-term adult nutritional insult of a highfat diet (HFD) on diencephalic DNA methylation of a selected gene, a member of the zinc fi nger family of proteins called zinc fi nger protein 91 homolog ( ZFP91 ). We compared the male and female offspring of dams exposed to different nutrition treatments (HFD vs. standard chow diet), and observed that male offspring of HFD-fed dams, which were born large according to the mean weight of their littermates (above the 80 percentile), had higher levels of DNA methylation in the ZFP91 promoter (unpublished data). Interestingly, the protein encoded by this gene is a potent survival factor for neurons and also acts as a regulator of the non-canonical NF-κ B pathway, and is a critical regulator in TNFSF14 . These pathways seem to be involved in the association of two principal components of the MS (65) .
Systems biology analysis revealed a highly predicted interaction between ZFP91 and CDKN2A (cyclin-dependent kinase inhibitor 2A) (Figure 4 ) , a gene that is not only highly expressed in the pancreas and central nervous system but has also been found to be strongly associated with T2D in Induction of the PPARGC1A promoter results in modulation of mitochondrial biogenesis, OXPHOS activity and coactivation of nuclear receptors involved in the regulation of metabolic functions (A, B and C). But the activity of the PPARGC1A promoter can be epigenetically regulated resulting in either repression or activation of gene transcription. For example, PPARGC1A is a putative target for epigenetically active drugs by the modulation of the acetylation-deacetylation switch mediated by Class III HDACs of the NAD + -dependent SIR family, which can repress the promoter activity. This repression signifi cantly impacts on the transcriptional machinery of several other genes modulated by PPARGC1A , for example, glucocorticoid receptor, ERR α and HIF1 α that also results in modulation of the mitochondrial biogenesis. PPARGC1A is, in addition, directly acetylated by another acetyltransferase enzyme, such as General Control Nonderepressible 5 (GCN5), a process that also results in a transcriptional repression of the PPARGC1A . On the contrary, post-translational modifi cations can positively regulate the activity of the PPARGC1A protein, either by direct phosphorylation mediated by AMPK or by deacetylation mediated by NAD-dependent deacetylase SIRT1. Some drugs and natural compounds can activate these two post-translational modifi cations, such as metformin and AICAR or resveratrol, respectively. GR , glucocorticoid receptor; THRA , thyroid hormone receptor α ; PPARS , peroxisome proliferator-activated receptors; ERR α , estrogen-related receptor α ; PPARGC1A , peroxisome proliferator-activated receptor γ , coactivator 1 α ; HIF1 α , hypoxia inducible factor 1, α subunit (basic helix-loop-helix transcription factor); SIRT1 , sirtuin 1; AMPK, 5 ′ AMP-activated protein kinase; OXPHOS, oxidative phosphorylation; GCN5, General Control Nonderepressible 5; HDACs, histone deacetylases; Sir2, silent information regulator-2. several genome-wide association studies (66, 67) . The aberrant methylation of CDKN2A has been described in tumors (68) , but its role in IR and T2D has not been reported. Hence, our fi nding may serve as a proof-of-concept on a putative role of the central nervous system, specifi cally, hypothalamic neurons, in the modulation of fetal programming of metabolism. In addition, our data may give some clues about the role of sexual dimorphism and fetal programming, because overnutrition during fetal life may interfere in a sex-specifi c manner and control mechanisms associated with metabolic regulation (69 To what extent are the epigenetic markers reversible by • environmental intervention, such as nutrigenomics ? Is there any potential for sequence-specifi c targeted • therapeutics ?
